Tackling Chronic Diseases Together: ADCAN Pharma & Inventia Sign Licensing & Tech Transfer Agreement for Cardiology and Diabetes!
Another exciting update from CPHI Milan! We have officially signed a licensing and technology transfer agreement with Inventia, a leading pharmaceutical company from India in presence of EDE. This strategic partnership is focused on our Cardiology and Diabetes therapy areas, aiming to provide better management solutions for these prevalent chronic conditions.
“This partnership with Inventia is a crucial step in ADCAN Pharma’s journey to provide comprehensive solutions for chronic diseases. The combined focus on Cardiology and Diabetes allows us to address two of the most pressing health challenges. By integrating Inventia’s technology and products, we are reinforcing our commitment to improving the quality of life for millions of patients. We are excited about the possibilities this collaboration creates.” Fokion Sinis, CEO of ADCAN Pharma
“Proud to collaborate with ADCAN to bring innovative and complex anti-diabetic and cardiac therapies to the UAE, addressing evolving healthcare needs and supporting better patient care. Our partnership goes beyond product introduction — we are also working towards localization at ADCAN, enabling a more sustainable and responsive supply ecosystem while serving growing local demand. By combining Inventia Healthcare’s complex product development capabilities with ADCAN’s local presence and capabilities, we aim to accelerate access to differentiated therapies, strengthen local pharmaceutical capabilities, and contribute meaningfully to the UAE’s healthcare ecosystem.” Pavan Bhat, Managing Director & CEO of Inventia
This collaboration is a key component of our strategy to expand our product portfolio and enhance our ability to address the growing burden of cardiovascular disease and diabetes. We are committed to leveraging Inventia’s expertise to bring high-quality, effective treatments to the market.
